Ensysce Biosciences Inc (ENSC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.46 (+1.24%), Market cap $0.00B, 52-week low–high $0.28 ~ $2.57.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8
Financial statements, price targets, institutional (13F) holdings and related news for Ensysce Biosciences Inc are updated in real time on BlackAll Trade.
Ensysce Biosciences Inc trades at $0.46 (+1.24%). Real-time quotes and charts are available on BlackAll Trade.
Ensysce Biosciences Inc has a market cap of about $0.00B.
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products